Wall Street brokerages predict that Aclaris Therapeutics, Inc. (NASDAQ:ACRS) will report $1.71 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Aclaris Therapeutics’ earnings, with the highest sales estimate coming in at $1.80 million and the lowest estimate coming in at $1.58 million. Aclaris Therapeutics reported sales of $2.05 million during the same quarter last year, which indicates a negative year-over-year growth rate of 16.6%. The company is scheduled to report its next earnings results on Friday, August 6th.
On average, analysts expect that Aclaris Therapeutics will report full-year sales of $6.92 million for the current fiscal year, with estimates ranging from $6.50 million to $7.40 million. For the next financial year, analysts expect that the company will report sales of $7.18 million, with estimates ranging from $6.41 million to $8.10 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, May 6th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.27). Aclaris Therapeutics had a negative return on equity of 107.60% and a negative net margin of 936.71%. The business had revenue of $1.78 million for the quarter, compared to the consensus estimate of $1.47 million.
NASDAQ ACRS traded down $0.02 on Friday, hitting $15.74. 4,356 shares of the company’s stock were exchanged, compared to its average volume of 903,643. Aclaris Therapeutics has a 52 week low of $1.82 and a 52 week high of $30.38. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.27 and a quick ratio of 9.27. The business has a 50-day moving average price of $18.95.
In other Aclaris Therapeutics news, insider David N. Gordon sold 2,631 shares of the stock in a transaction dated Tuesday, July 13th. The stock was sold at an average price of $16.98, for a total transaction of $44,674.38. Following the completion of the sale, the insider now directly owns 147,447 shares in the company, valued at approximately $2,503,650.06. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Frank Ruffo sold 27,339 shares of the firm’s stock in a transaction dated Monday, April 26th. The shares were sold at an average price of $25.80, for a total value of $705,346.20. Following the completion of the sale, the chief financial officer now owns 209,059 shares of the company’s stock, valued at $5,393,722.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 122,138 shares of company stock valued at $2,856,286. 8.20% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of ACRS. Royal Bank of Canada grew its stake in Aclaris Therapeutics by 85.6% in the 1st quarter. Royal Bank of Canada now owns 3,515 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 1,621 shares in the last quarter. Dorsey Wright & Associates grew its position in Aclaris Therapeutics by 135.0% in the first quarter. Dorsey Wright & Associates now owns 6,110 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 3,510 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Aclaris Therapeutics by 6.2% in the first quarter. Bank of New York Mellon Corp now owns 111,156 shares of the biotechnology company’s stock worth $2,801,000 after purchasing an additional 6,537 shares during the last quarter. HighTower Advisors LLC lifted its stake in Aclaris Therapeutics by 12.1% in the first quarter. HighTower Advisors LLC now owns 64,478 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 6,978 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Aclaris Therapeutics in the first quarter worth $204,000. 87.15% of the stock is currently owned by institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation.
Featured Article: What is the formula for calculating total return?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.